UBS Group’s Ionis Pharmaceuticals IONS Stock Holding History

UBS Group’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-500	Closed	-$24K	–	7781
2016 Q4	$24K	Hold	500	–	–	﹤0.01%	6399
2016 Q3	$18K	Sell	500 -90,000	-99%	-$2.82M	﹤0.01%	6378
2016 Q2	$2.11M	Buy	90,500 +90,000	+18,000%	+$2.9M	﹤0.01%	2738
2016 Q1	$20K	Sell	500 -2,000	-80%	-$81.2K	﹤0.01%	6202
2015 Q4	$155K	Hold	2,500	–	–	﹤0.01%	4872
2015 Q3	$101K	Sell	2,500 -100	-4%	-$5.18K	﹤0.01%	5229
2015 Q2	$150K	Sell	2,600 -800	-24%	-$50.9K	﹤0.01%	5107
2015 Q1	$216K	Sell	3,400 -6,900	-67%	-$468K	﹤0.01%	4816
2014 Q4	$636K	Buy	+10,300	New	+$508K	﹤0.01%	3975

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

UBS Group's IONS Position: Q2 2026 in Review

UBS Group reduced its Ionis Pharmaceuticals (IONS) stake by 23% in Q2 2026, selling an estimated $13.8M and leaving 624,874 shares worth $49.5M. The position accounts for 0.01% of the portfolio, ranked #1752.

UBS Group first reported a position in IONS in Q4 2014 and has held it in 47 quarters since. The position peaked at $82.7M in Q4 2025. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

UBS Group held 624,874 shares of Ionis Pharmaceuticals worth $49.5M as of Q2 2026.
UBS Group sold 183,569 Ionis Pharmaceuticals shares in Q2 2026, an estimated $13.8M.
Ionis Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q2 2026, its #1752 holding.
UBS Group first reported a position in Ionis Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
UBS Group's Ionis Pharmaceuticals position peaked at $82.7M in Q4 2025.
514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.